This is a preview of subscription content, log in via an institution to check access.
References
Gupta RA, Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1:11–21.
Nissen SE: Adverse cardiovascular effects of rofecoxib. N Engl J Med 2006, 355:203–204.
Arber N, Eagle CJ, Spicak J, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885–895.
Bertagnolli MM, Eagle CJ, Zauber AG, et al.: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873–884.
Jones R, Rubin G, Berenbaum F, Scheiman J: Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Med 2008, 121:464–474.
McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633–1644.
Rights and permissions
About this article
Cite this article
Kraus, S., Arber, N. Rofecoxib and cardiovascular adverse effects: New insights. Curr colorectal cancer rep 5, 3–4 (2009). https://doi.org/10.1007/s11888-009-0001-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11888-009-0001-1